Who Brands - Brand Ownership DirectoryWho Brands
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
Who Brands

Your trusted reference for brand ownership information. We provide factual, comprehensive data about who owns the brands you know.

Stay in the know

Get the latest ownership updates delivered to your inbox.

Browse

  • All Brands
  • Categories
  • Companies
  • Countries
  • Compare Brands
  • Blog
  • Brand Quiz
  • RSS Feed

Company

  • About Us
  • Methodology
  • Contact
  • FAQ
  • Submit a Brand
  • List Your Brand
  • Write for Us

Legal

  • Terms of Service
  • Privacy Policy
  • Cookie Policy
  • Affiliate Disclosure
  • Disclaimer

Support Us

☕Buy me a coffee

2026 Who Brands. All information is provided for educational purposes. Brand names and logos are trademarks of their respective owners.

  1. Home
  2. Brands
  3. Healthcare & Pharmaceuticals
  4. Alcon
Alcon logo
Healthcare & Pharmaceuticals

Who Owns Alcon?

Alcon Inc. is an independent, publicly traded global eye care company with no parent company. It was spun off from Novartis AG in April 2019 and trades on both the NYSE (ALC) and the SIX Swiss Exchange (ALC). Founded in 1945 in Fort Worth, Texas, by pharmacists Robert and William Conron, Alcon is the world's largest eye care device company by revenue, generating approximately $10.2 billion in annual sales.

Parent Company

Alcon Inc.

Founded

1945

Status

Publicly Traded

Headquarters

Geneva, Switzerland

premiumleaderGlobalunisexenergy efficiencyreduced wasteOfficial Website

Who Owns Alcon?

  • Parent Company: Alcon Inc.
  • Ownership Type: Publicly traded
  • Company Type: Publicly Traded
  • Stock Ticker: NYSE: ALC
BrandParent CompanyOwnership Type
AlconAlcon Inc.Publicly traded

Where to Buy

Disclosure: We may earn commission from purchases
AmazonAlcon on Amazon

History of Alcon

  • Founded: 1945
  • Founders: Robert Conron, William Conron

Alcon was founded in 1945 by brothers Robert and William Conron, both pharmacists, in Fort Worth, Texas. The company name is derived from their surname. The Conron brothers concentrated initially on ophthalmic pharmaceutical preparations, products used directly in eye care practice that larger companies were not prioritizing at the time.

Through the 1950s and 1960s, Alcon extended its product range into contact lens care solutions and eye drops. The Opti-Free contact lens solution, launched in later decades, became one of the most widely used lens care products globally. Systane artificial tears, also developed under Alcon, became a widely recognized dry eye treatment brand.

Nestlé acquired Alcon in 1977, providing capital for international expansion. Under Nestlé ownership, Alcon built out manufacturing facilities outside the United States and expanded into surgical equipment for ophthalmology. Novartis began acquiring Alcon from Nestlé in 2008, completing full ownership by 2010 in a deal valued at approximately $52 billion at close. Alcon operated as a division of Novartis for the following nine years.

In June 2018, Novartis announced plans to separate Alcon as an independent company. The spin-off was completed on April 9, 2019. Alcon relocated its global headquarters from Fort Worth to Geneva, Switzerland, and began operating with its own board, management team, and balance sheet.

Since independence, Alcon has pursued acquisitions to expand its product lines. In 2022, Alcon acquired Aerie Pharmaceuticals, a glaucoma drug company, for approximately $770 million. In March 2025, Alcon announced the acquisition of LENSAR, a maker of robotic femtosecond laser systems for cataract surgery, for approximately $356 million. Both acquisitions were funded from Alcon's own balance sheet and credit facilities without Novartis involvement.

About Alcon Inc.

What does Alcon own?
Alcon owns a portfolio of eye care brands across two business segments. In Surgical, the company owns intraocular lens brands including Clareon, PanOptix, and AcrySof, surgical equipment brands, and consumable products. In Vision Care, Alcon owns contact lens brands including TOTAL30, PRECISION7, DAILIES, and Air Optix, and ocular health brands including Systane and Tryptyr. The company also owns Aerie Pharmaceuticals, which produces glaucoma treatments.

Is Alcon publicly traded?
Yes, Alcon Inc. trades on the New York Stock Exchange under ticker ALC and on the SIX Swiss Exchange under the same ticker. The company was spun off from Novartis in April 2019 and began trading as an independent company. Alcon is incorporated in Switzerland and headquartered in Geneva.

Who founded Alcon?
Alcon was founded in 1945 by Robert Conron and William Conron in Fort Worth, Texas. The company's name is derived from the first syllables of "Alex" and "Conron." The founders initially focused on manufacturing ophthalmic products, including sterile ophthalmic solutions and instruments for eye surgery. Alcon was later acquired by Nestle in 1977 and then by Novartis in 2010 before being spun off as an independent company in 2019.

Where is Alcon headquartered?
Alcon is headquartered in Geneva, Switzerland. The company was incorporated in Switzerland ahead of its 2019 spin-off from Novartis. Alcon maintains significant operations in Fort Worth, Texas, where it was originally founded, along with manufacturing facilities in Switzerland, the United States, Mexico, Japan, China, India, and Belgium.

How many brands does Alcon own?
Alcon owns multiple eye care brands across its Surgical and Vision Care segments. Key brands include TOTAL30, PRECISION7, DAILIES, Air Optix, Systane, Tryptyr, PanOptix, Clareon, and Aerie Pharmaceuticals products. The company's portfolio is focused exclusively on eye care, with products spanning contact lenses, ocular health treatments, intraocular lenses, and surgical equipment.

Who owns Alcon?
Alcon is a publicly traded corporation owned by its shareholders. Major institutional holders include Vanguard Group, BlackRock, and other large asset managers. Novartis distributed all of its Alcon shares to Novartis shareholders in the April 2019 spin-off, retaining no ownership stake. No single shareholder holds a controlling interest in the company.

What is Alcon's revenue?
In FY2025, Alcon reported net sales of $10.3 billion, up 5% as reported and 4% on a constant currency basis. Diluted earnings per share were $1.98, and core diluted EPS was $3.07. The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow. In Q1 2026, net sales were $2.69 billion, up 10% as reported.

Has Alcon made any recent acquisitions?
Yes, Alcon has been active in acquisitions. In 2025, the company acquired a majority interest in Aurion Biotech for approximately $522 million, completed the acquisition of LumiThera for $124 million, and acquired approximately 91.2% of Cylite Pty Ltd. In March 2025, Alcon agreed to acquire LENSAR for up to $430 million, but terminated the agreement in March 2026. In 2022, Alcon acquired Aerie Pharmaceuticals for approximately $770 million.

  • Founded: 1945
  • Headquarters: Geneva, Switzerland
  • Company Type: Publicly Traded
  • Stock: NYSE: ALC
  • Revenue: $10.3 billion (FY2025)
  • Employees: Approximately 27,000

Visit Alcon Inc. website

View full company profile for Alcon Inc.

Where Is Alcon Made / Based?

  • Headquarters: Geneva, Switzerland
  • Manufacturing / Operations: United States, Switzerland, Mexico, Japan, China, India, Belgium, Singapore

Alcon Categories & Tags

Eye CareContact LensesOphthalmicSurgical EquipmentVision Care

Alcon Sustainability & Ethics

Alcon publishes an annual sustainability report under its "Brilliant Planet" environmental framework. As of the 2024 report, 17 of 18 manufacturing sites held ISO 14001:2015 environmental management certification. Approximately 70% of manufacturing sites operate as landfill-free for non-hazardous waste.

Alcon has set targets to reduce absolute Scope 1 and 2 greenhouse gas emissions. The company's 2024 sustainability report documented progress toward these targets but did not claim net-zero certification. No third-party carbon-neutral certification from a body such as Science Based Targets initiative (SBTi) has been confirmed for Alcon's full operations as of May 2025.

Through its "Brilliant Lives" social impact program, Alcon has committed funds and resources to improving vision access in underserved communities. The company reported investing approximately $42 million annually in eye care infrastructure and training in low-income markets.

Alcon's contact lens manufacturing processes use significant volumes of water. The company's sustainability reports document water use by facility but do not claim water-neutral status.

Awards & Recognition

Alcon's Dailies Total1 contact lens received recognition from the American Academy of Optometry at its annual meeting for its water gradient silicone hydrogel technology, which delivers a reported 80% water content at the lens surface. This is a verifiable clinical and technical claim documented in peer-reviewed literature.

Alcon's NGENUITY 3D visualization system has been referenced in peer-reviewed ophthalmology publications as a significant development in vitreoretinal surgery technique, enabling surgeons to operate while viewing a 3D display rather than through an operating microscope eyepiece.

Alcon's PanOptix trifocal intraocular lens was the first trifocal IOL to receive FDA approval for use in the United States, cleared in 2019. This regulatory milestone is a verifiable fact documented in FDA clearance records.

Alcon Recalls & Controversies

December 2024 Systane recall: Alcon Laboratories issued a voluntary nationwide recall of one lot of Systane Lubricant Eye Drops Ultra PF (Lot 10101) due to potential fungal contamination. The recall was initiated after a consumer complaint identified foreign material inside a sealed single-use vial. The FDA classified the recall and noted that use of contaminated eye drops could cause eye infections that may be vision-threatening. No adverse events were reported at the time of the recall announcement. The affected lot had an expiration date of September 2025.

Aerie Pharmaceuticals drug pricing: Following the 2022 acquisition of Aerie Pharmaceuticals, Alcon assumed the marketing of glaucoma drugs Rocklatan and Rhopressa. Patient advocacy organizations have raised concerns about the pricing of branded glaucoma medications generally, though no specific enforcement action related to these drugs has been announced against Alcon as of May 2025.

Contact lens environmental impact: Industry analysts and environmental researchers have raised concerns about single-use daily contact lens waste, noting that billions of lenses and their packaging are disposed of annually. Alcon is one of the major producers of daily disposable lenses. The company has not announced a formal recycling program for daily disposable lenses in the United States as of May 2025, in contrast to some competitors who have launched such programs.

No major FDA Warning Letters have been issued to Alcon manufacturing facilities as of May 2025, per publicly available FDA inspection records.

Alcon Ownership: Pros & Cons

Advantages

  • +Independent structure gives Alcon full strategic autonomy, with no competing priorities from a pharmaceutical parent
  • +Dual listing on NYSE and SIX Swiss Exchange provides access to US and European capital markets
  • +Exclusive focus on eye care, with R&D spending of approximately $850 million per year directed entirely at ophthalmic products
  • +Leading market positions in intraocular lenses (approximately 38% share) and lens care solutions (approximately 40% share) create durable competitive footing
  • +Acquisitions of Aerie Pharmaceuticals (2022) and LENSAR (2025) extend the portfolio into higher-growth surgical and pharmaceutical segments

Considerations

  • -Alcon carries meaningful debt from its spin-off balance sheet and subsequent acquisitions, which limits financial flexibility
  • -Disposable contact lens waste is a growing reputational risk as regulatory pressure on single-use plastics increases in the EU and elsewhere
  • -The Vision Care segment faces sustained competitive pressure from Johnson and Johnson Vision and CooperVision in daily disposable lenses
  • -Currency exposure is significant, with revenues across dozens of currencies and the reporting currency being the US dollar
  • -The Aerie drug portfolio faces biosimilar and generic competition pressure as patents on glaucoma pharmaceutical ingredients age

Frequently Asked Questions About Alcon

Sources & Further Reading

  • Alcon Official Website
  • Alcon Investor Relations
  • SEC EDGAR: Alcon 20-F and 6-K Filings
  • NYSE: Alcon (ALC)
  • Alcon Annual Report 2024
  • Alcon Sustainability Report
  • FDA Recall Database
  • American Academy of Ophthalmology
  • American Society of Cataract and Refractive Surgery
  • World Health Organization: Vision Health
  • Wikidata: Alcon Inc.

Competitors to Alcon

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

BrandParent CompanyCountryFoundedMarket PositionPrimary MarketGender Target
AcuvueAcuvue
Johnson Johnson
USA
1987
Mass marketGlobalAll Genders
Bausch + LombBausch + Lomb
Bausch Lomb
Canada
1853
LeaderGlobalUnisex
ClearLabClearLab
Menicon
Singapore
2006
Mass marketAsia pacificUnisex
CooperVisionCooperVision
Coopercompanies
USA
1980
LeaderGlobalUnisex
MeniconMenicon
Menicon
Japan
1951
LeaderAsia pacificUnisex

Learn More About Competitors

AcuvueHealthcare Pharmaceuticals

Acuvue

Owned by Johnson & Johnson

Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.

contact-lensesvision-carejohnson-and-johnson
Bausch + LombHealthcare Pharmaceuticals

Bausch + Lomb

Owned by Bausch + Lomb Corporation

Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.

contact-lensesvision-carebausch-lomb
ClearLabHealthcare Pharmaceuticals

ClearLab

Owned by Menicon Co., Ltd.

Contact lens brand owned by Menicon, headquartered in Singapore, producing biocompatible daily disposable and monthly silicone hydrogel lenses for Asia-Pacific and global markets.

contact-lensesvision-caredaily-disposables
CooperVisionHealthcare Pharmaceuticals

CooperVision

Owned by The Cooper Companies, Inc.

Global contact lens manufacturer and division of CooperCompanies, known for Biofinity, MyDay, Clariti, and MiSight myopia management lenses. Strong in toric and multifocal fittings.

contact-lensesvision-carecoopervision
MeniconHealthcare Pharmaceuticals

Menicon

Owned by Menicon Co., Ltd.

Japan's first and largest contact lens manufacturer, founded in 1951 in Nagoya. Known for rigid gas permeable lenses, orthokeratology, and expanding daily disposable silicone hydrogel products.

contact-lensesvision-carergp-lenses

Competitive Analysis

Market Positioning: Alcon competes with 5 brands in the same categories, ranging from mass market to luxury positioning.

Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.

Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.

Independent Alternatives to Alcon

Looking for brands with different ownership structures? These similar brands are not owned by Alcon Inc., giving you alternative choices that support different corporate structures.

MeniconHealthcare Pharmaceuticals

Menicon

Owned by Menicon Co., Ltd.

Japan's first and largest contact lens manufacturer, founded in 1951 in Nagoya. Known for rigid gas permeable lenses, orthokeratology, and expanding daily disposable silicone hydrogel products.

contact-lensesvision-carergp-lenses
Publicly Traded

Menicon operates independently without a large parent corporation.

Bausch + LombHealthcare Pharmaceuticals

Bausch + Lomb

Owned by Bausch + Lomb Corporation

Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.

contact-lensesvision-carebausch-lomb
Publicly Traded

Bausch + Lomb operates independently without a large parent corporation.

GE HealthCareHealthcare Pharmaceuticals

GE HealthCare

Owned by GE HealthCare Technologies Inc.

Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.

healthcare-technologymedical-imagingdiagnostics
Publicly Traded

GE HealthCare operates independently without a large parent corporation.

HerbalifeHealthcare Pharmaceuticals

Herbalife

Owned by Herbalife Ltd.

Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.

nutritiondietary-supplementsweight-management
Publicly Traded

Herbalife operates independently without a large parent corporation.

Novo NordiskHealthcare Pharmaceuticals

Novo Nordisk

Owned by Novo Nordisk

Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.

pharmaceuticalsdiabetesobesity
Publicly Traded

Novo Nordisk operates independently without a large parent corporation.

PfizerHealthcare Pharmaceuticals

Pfizer

Owned by Pfizer Inc.

American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.

pharmaceuticalvaccinesmedicines
Publicly Traded

Pfizer operates independently without a large parent corporation.

Alcon Inc. Stock Information

Jobs at Alcon Inc.

Latest News About Alcon

Related Articles About Alcon

View more articles
Toy Brand Ownership: From LEGO to Hasbro
Entertainment

Toy Brand Ownership: From LEGO to Hasbro

LEGO is family-owned by the Kirk Kristiansens. Hasbro and Mattel are Wall Street-owned. Bandai Namco owns Tamagotchi. Discover who owns the biggest toy brands and why it matters. Explore our database.

Who Brands StaffSep 4, 2026
ToysLegoHasbro
Video Game Brands and Their Corporate Parents
Pop Culture

Video Game Brands and Their Corporate Parents

EA sold for $55B to Saudi Arabia's PIF, Silver Lake and Kushner's Affinity. Microsoft bought Activision Blizzard for $75.4B. Tencent owns Riot, Supercell, and stakes in Epic. Sony bought Bungie for $3.6B. Discover video game brands and their corporate parents.

Who Brands StaffSep 3, 2026
Video GamesAcquisitionsEa
Brands That Appeared in Super Bowl Ads Then Got Acquired
Pop Culture

Brands That Appeared in Super Bowl Ads Then Got Acquired

Poppi ran a Super Bowl ad in February 2025 and PepsiCo bought it for $1.95B. Grubhub debuted in Super Bowl LX after Wonder acquired it for $650M. WeatherTech ran its 14th ad. Discover brands that appeared in Super Bowl ads then got acquired.

Who Brands StaffSep 2, 2026
Super BowlAcquisitionsPoppi
View more articles

People Also Searched

Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase
Brandpharmaceutical

Abbokinase

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Accutane
Branddermatology

Accutane

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Activase
Brandpharmaceutical

Activase

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment
Browse All Healthcare & Pharmaceuticals

Last reviewed: May 25, 2025 · Reviewed by Who Brands Editorial Team